Progyny, Inc. Common Stock
PGNYProgyny, Inc. (PGNY) is a healthcare company that specializes in fertility benefits management. It provides comprehensive fertility solutions and coverage options for employers and health plans, aiming to improve access to fertility treatments and support individuals and couples on their reproductive journey.
Company News
Progyny's CEO Peter Anevski purchased 79,500 shares worth approximately $1.9 million, increasing his direct ownership to 680,251 shares. The purchase signals confidence in the company's performance, which has seen 9% sales growth and near-100% customer retention.
Progyny, Inc. (PGNY) will report its Q1 2025 financial results on May 8, 2025, and host a conference call to discuss the results.
Progyny, Inc. disclosed the loss of a significant client representing 12% of its revenue, causing a 32.7% drop in its stock price. The Law Offices of Frank R. Cruz is investigating the company for possible violations of federal securities laws.
JMP Securities initiated coverage on Progyny, a company specializing in fertility benefits, with an 'Outperform' rating due to its growth potential. The firm set a price target of $36, citing Progyny's unique platform and strong performance with over 450 clients and 6 million members.
Enhabit (EHAB) delivered earnings and revenue surprises of 40% and 2.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
